Iktos and Elsevier announce their partnership

Iktos and Elsevier announced a partnership (March 5, 2024) combining "the world's largest chemistry database, Reaxys from Elsevier, with cutting-edge AI from Iktos" to build a platform focused on predictive retrosynthesis and synthetic accessibility. The stated aim is to help pharmaceutical companies identify pre-clinical drug candidates faster by pairing Elsevier's chemistry database with Iktos' AI capabilities. No specific financial terms, timelines, or quantified outcomes are disclosed on the page.

Iktos is a generative-AI drug-design company whose de novo molecule-design platform is used directly by partner pharma companies' medicinal chemists.

This sits in the Build stage of the AI use-case lifecycle: Named examples from the foundation-model labs and platforms pharma teams use to actually construct, train and generate the model or application.